Blood pressure, arterial function, structure, and aging: The role of hormonal replacement therapy in postmenopausal women

Journal of Clinical Hypertension

Volumn 5, Issue 3, 2003, Pages 219-225

  Scuteri, Angelo ^a   Ferrucci, Luigi ^a  

^a INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE;

AGING; ARTERY DIAMETER; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INDIVIDUALIZATION; LIFE EXPECTANCY; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; PHYSICIAN; POSTMENOPAUSE; PREDICTION; PRESCRIPTION; PUBLIC HEALTH; PUBLICATION; PULSE PRESSURE; REVIEW; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; ADULT; ARTERY; BLOOD PRESSURE; ESTROGEN THERAPY; PATHOLOGY; PHYSIOLOGY;

ADULT; AGING; ARTERIES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 0141687200     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.00683.x     Document Type: Review

References (54)

1. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-333.
3. Flechter SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288:366-368.
4. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
5. Kalache A, Aboderin I. Stroke: the global burden. Health Policy Plan. 1995;10:1-21.
6. Bonita R. Epidemiology of stroke. Lancet. 1992;339:342-344.
7. Yong LC, Kuller LH, Rutan G, et al. Longitudinal study of blood pressure changes and determinants from adolescence to middle age. The Dormont High School Follow-Up Study, 1957-1963 to 1989-1990. Am J Epidemiol. 1997;138:973-983.
8. Burt VI, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results of the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
9. Stamler J, Stamler R, Riedlinger WF, et al. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) Program, 1973-1975. JAMA. 1976; 235:2299-2306.
10. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol. 1994;140:669-682.
11. Mozersky DJ, Summer DS, Hokanson DE, et al. Transcutaneous measurements of the elastic properties of the human femoral artery. Circulation. 1972;46:948-955.
12. Scuteri A, Cacciafesta M, Di Bernardo MG, et al. Pulsatile versus steady-state component of blood pressure in elderly females: an independent risk factor for cardiovascular disease? J Hypertens. 1995;13:185-191.
13. Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension. 1997;30:1410-1415.
14. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999;100:354-360.
15. Avolio AP, Cheng SG, Wang RP, et al. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation. 1983;68:50-58.
16. Laogun AA, Gosling RG. In vivo arterial compliance in man. Clin Phys Physiol Meas. 1982;3:201-212.
17. Nabulsi A, Folsom A, Szklo M, et al., for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Is menopausal status or hormone replacement therapy associated with carotid intimal-medial wall thickness [abstract]? Am J Epidemiol. 1992;136:1003-1004.
18. Staessen J, Bulpitt CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3:427-433.
19. Seeley EW, Walsh BW, Gerhard MD, et al. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension. 1999;33(5):1190-1194.
20. Cagnacci A, Rovati L, Zanni A, et al. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am J Physiol. 1999;276(4 pt 2): H1355-H1360.
21. Matthews KA, Meilhan E, Kuller LH. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-645.
22. van Beresteyn EC, van't Hof MA, De Waard H. Contributions of ovarian failure and aging to blood pressure in normotensive perimenopausal women: a mixed longitudinal study. Am J Epidemiol. 1989;129:947-955.
23. Barret-Connor E, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA. 1991;265:627-631.
24. Lip G, Beevers M, Churchill D, et al. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens. 1994;8:491-494.
25. Hayward CS, Knight DC, Wren BG, et al. Effect of hormone replacement therapy on non-invasive cardiovascular haemodynamics. J Hypertens. 1997;15:987-993.
26. Lind T, Cameron EC, Hunter WM, et al. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol. 1979;86 (suppl 3):1-30.
27. Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas. 1983;5:135-142.
28. Scuteri A, Lakatta EG, Bos AJG, et al. Effect of estrogen and progestin replacement on arterial stiffness indices in postmenopausal women. Aging Clin Exp Res. 2001;13:122-130.
29. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199-208.
30. Scuteri A, Bos AJG, Brant LJ, et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med. 2001;135:229-238.
31. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605-613.
32. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
33. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
34. Grady D, Hulley SB. Hormones to prevent coronary disease in women: when are observational studies adequate evidence? Ann Intern Med. 2000;133:999-1001.
35. Rajkumar C, Kingwell BA, Cameron JA, et al. Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol. 1997;30:350-356.
36. McGrath BP, Liang YL, Teede H, et al. Age-related deterioration in arterial structure and function in postmenopausal women. Impact of hormone replacement therapy. Arterisocler Thromb Vasc Biol. 1998,18:1149-1156.
37. Jonas HA, Kronmal RA, Psaty BM, et al., for the CHS Collaborative Research group. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. Ann Epidemiol. 1996;6:314-323.
38. Westendorp ICD, Veld I, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery. The Rotterdam Study. Stroke. 1999;30:2562-2567.
39. Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women: ACAPS Investigators: Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-1019.
40. Stampfer MJ, Colditz GA, Willett WC. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 1993; 325:756-762.
41. Mercuro G, Zoncu S, Paoletti AM, et al. Study of myocardial contractility by pulsed wave Doppler tissue imaging does not reveal an inotropic effect of estrogen at physiologic dose. Am J Cardiol. 1999;83:1677-1679.
42. Prelevic GM, Beljic T. The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas. 1994;20:37-44.
43. Hayward C, Kalnins WV, Kelly RP. Acute effects of 17-estradiol on ventricular and vascular hemodynamics in postmenopausal women. Am J Physiol Heart Circ Physiol. 2000; 279:H2277-H2284.
44. Gilligan D, Quyyumi AA, Cannon RO. Effect of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
45. Collins P, Rosano GMC, Jiang C, et al. Cardiovascular protection by estrogen - a calcium antagonist effect. Lancet. 1993; 341:1264-1265.
46. Fischer G, Swain M. Effect of sex hormones on blood pressure and vascular connective tissue in castrated and noncastrated male rats. Am J Physiol. 1977;232:H617-H621.
47. Vargas R, Wroblewska B, Rego A, et al. Oestradiol inhibits smooth muscle cell proliferation of pig coronary arteries. Br J Clin Pharmachol. 1993; 109:612-617.
48. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab. 2000;85:1577-1583.
49. Best PJ, Berger PB, Miller VM, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med. 1998;128:285-288.
50. Grodstein F, Stampfer MJ, Manson JE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
51. Meirik O. Effect of different progestins in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582-1588.
52. Miyagawa K, Rosch J, Stanczyk F, et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
53. Register TC, Adams MR, Golden DL, et al. Conjugated equine estrogen alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscl Thromb Vasc Biol. 1998;18:1164-1171.
54. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.